Quanta Announces Dosing of First Patient in Phase 1/1b Clinical Trial of QTX3046, an Oral KRASG12D-Selective Dual-State Allosteric Inhibitor, and Other Program Updates by Seini Moimoi | Jun 27, 2024 | Portfolio News
Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes by Seini Moimoi | Jun 25, 2024 | Portfolio News
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec by Seini Moimoi | Jun 18, 2024 | Portfolio News
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies by Seini Moimoi | Jun 17, 2024 | Portfolio News
Somatus Achieves 4-Star Rating for Health Plan Partner Kidney Population Through Whole-Person Clinical Quality Program by Seini Moimoi | Jun 12, 2024 | Portfolio News
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease by Seini Moimoi | Jun 11, 2024 | Portfolio News
